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Abstract
Introduction: Survival of transplant patients and grafts depends largely on the use of immuno-
suppressive drugs. However, a balance remains to be established among immunosuppression,
transplant rejection and cytomegalovirus (CMV) infection, which results in a high rate of
morbidity and mortality. The aim of this study was to deﬁne a better strategy for monitor-
ing transplanted patients based on the analysis of the blood concentration of sirolimus and
tacrolimus and the burden of CMV.
Methods: Fifty ﬁve post-transplant (kidney and liver) pediatric patients, nine treated with
sirolimus and 46 treated with tacrolimus, were included. A total of 541 measurements were
obtained. In each measurement the concentration of immunosuppressant in whole blood and
CMV viral load in plasma and whole blood was quantiﬁed by real-time PCR. Pearson correlation
coefﬁcient (r) was estimated.
Results: Values of r ≤0.0747 were found for the relationship between dose and concentration
of immunosuppressant; r = 0.9406 for the relationship between viral load in whole blood and
plasma, and r ≤0.4616 for the relationship between concentration of immunosuppressant and
viral load.∗ Corresponding author.
E-mail address: brisalm@yahoo.com.mx (B. López-Martínez).
444-3409/© 2016 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A. This is an open access article under 
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
CMV and immunosuppressive drugs in transplant patients 5
Conclusions: These data support that the doses of immunosuppressive drugs do not correlate
with the levels of the same in whole blood. Therefore, systemic levels of immunosuppressant
should be constantly monitored together with CMV load. Meanwhile, a high correlation between
viral load measured in whole blood and plasma was found.
© 2016 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Correlación entre la carga viral de citomegalovirus y los niveles de tacrolimus y
sirolimus en pacientes pediátricos trasplantados
Resumen
Introducción: La supervivencia de pacientes trasplantados y de los injertos depende en gran
medida del uso de fármacos inmunosupresores. Sin embargo, aún no se ha logrado establecer un
balance entre la inmunosupresión, el rechazo al trasplante y la infección por citomegalovirus
(CMV), lo cual deriva en una alta tasa de morbilidad y mortalidad. El objetivo de este trabajo
fue deﬁnir una mejor estrategia de seguimiento de los pacientes trasplantados a partir del
análisis de la concentración en sangre de sirolimus y tacrolimus y la carga de CMV.
Métodos: Se incluyeron 55 pacientes pediátricos post-trasplante (rin˜ón e hígado), nueve en
tratamiento con sirolimus y 46 en tratamiento con tacrolimus. Se obtuvieron 541 mediciones
en total. En cada medición se cuantiﬁcó la concentración de inmunosupresor en sangre total
y la carga viral de CMV en plasma y sangre total mediante PCR en tiempo real. Se calculó el
coeﬁciente de correlación de Pearson (r).
Resultados: Se encontraron valores de r ≤ 0.0747 para la relación entre dosis y concentración
del inmunosupresor; de r = 0.9406 para la relación de la carga viral entre suero y sangre total
y de r ≤ 0.4616 para la relación entre concentración de inmunosupresor y carga viral.
Conclusiones: Estos datos apoyan que la dosis de los fármacos inmunosupresores no correlaciona
con los niveles de los mismos en sangre total. Por ello, deben ser constantemente monitoreados
junto con la carga viral. Por su parte, se encontró alta correlación entre la carga viral medida
en sangre total y plasma.
© 2016 Hospital Infantil de México Federico Gómez. Publicado por Masson Doyma México S.A.
Este es un artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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t1. Introduction
Solid organ transplant (SOT) is a viable option for the treat-
ment of childhood diseases that result in end organ failure.
According to the Organ Procurement and Transplantation
Network (OPTN) in the U.S. in 2008, almost 2000 pediatric
patients (<18 years) received an organ transplant, repre-
senting 7.6% of all transplants performed. The majority of
those transplants were kidney followed by liver. Among the
principal problems associated with the transplant are graft
rejection and infection due to cytomegalovirus (CMV).1,2
CMV or human herpesvirus 5 was initially isolated from
the salivary glands and kidneys of children.3 It received
the name of cytomegalovirus because it produces typical
cytomegalic inclusions in the affected cells.4,5 In 1965 it was
isolated in a kidney transplant recipient.6 Infection caused
by CMV is present in 90% of the world population, usually
7since childhood. In patients who are immunocompromised,
such as patients with SOT, CMV is one of the principal causes
of morbidity and mortality because it causes clinical effects
such as viral syndrome by CMV, fatigue, organ failure and
e
I
u
traft rejection.8 In addition, these effects are associated
ith an increase in hospitalization costs.8--12
Despite advances in the development of immunosup-
ressive agents, a balance between therapy to prevent
ejection and, at the same time, preserve the ability of
he immune system to control or prevent infectious pro-
esses has not been found. Two of the most commonly
sed immunosuppressants are tacrolimus and sirolimus. Cur-
ently, for management of patients with SOT, the best
trategy to prevent rejection associated with insufﬁcient
oncentrations of immunosuppressant and CMV disease is
o individualize therapy. Preventing rejection is achieved
y routinely quantifying the immunosuppressant levels in
lood to keep them within the therapeutic range. In regard
o CMV disease, prevention is carried out by monitoring the
iral load in whole blood and/or plasma.13--16 The solid organ
ransplant program of the Hospital Infantil de México Fed-
rico Gómez (HIMFG) is one of the main programs in Mexico.
n that institution no studies have been carried out that doc-
ment the quantitative relationship between the dose and
he blood levels of the immunosupresant or that show the
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elationship  between  the  blood  level  of  the  immunosupp-
essant and  CMV  viral  load  in  whole  blood  and  in  plasma.
he goal  of  this  investigation  was  to  describe  the  correla-
ion between  the  blood  level  of  tacrolimus  and  sirolimus
mmunosuppressant  agents  and  CMV  viral  load  in  pediatric
atients with  kidney  or  liver  transplant  from  the  HIMFG.
. Methods
.1.  Study  population
he  study  was  conducted  at  the  Clinical  Laboratory
epartment of  the  HIMFG  between  May  2011  and  June
012. Pediatric  patients  with  kidney  or  liver  transplant
ho were  undergoing  immunosuppressant  treatment  with
acrolimus or  sirolimus  were  included.  The  study  included
ine post-kidney  transplant  patients  undergoing  ther-
py with  sirolimus  as  immunosuppressant.  From  these
atients, 13  measurements  were  done.  The  study  also
ncluded 46  patients  undergoing  treatment  with  tacrolimus
s immunosuppressant  (20  post-liver  transplant  and  26
ost-kidney transplant).  There  were  528  measurements
one from  the  group  of  patients  undergoing  therapy  with
acrolimus.
The study  was  approved  by  the  Scientiﬁc  Research  and
thics Committees  of  the  HIMFG.  Throughout  the  study  the
dentity of  the  patients  remained  conﬁdential,  although  the
eries of  clinical  tests  done  is  part  of  the  routine  follow-up
erformed after  transplantation  as  a  strategy  to  reduce  the
isk of  CMV  disease.
.2.  Quantiﬁcation  of  sirolimus  in  whole  blood
or  quantiﬁcation  of  sirolimus,  pre-treatment  using  a
50-l sample  of  whole  blood  and  300  l  precipitating
eagent from  ARCHITECT  Sirolimus  Whole  Blood  Precipita-
ion Reagent®  (Abbott  Laboratories)  was  carried  out.  The
ixture was  incubated  at  42 ◦C  for  10  min.  It  was  then
entrifuged for  7  min  at  13,000  rpm,  and  the  supernatant
as separated  in  a  pretreatment  tube  for  immunosup-
ressive techniques  (1P06-01®,  Abbott  Laboratories).  The
ixture was  centrifuged  for  30  sec  and  ﬁnally  quantiﬁed
ith the  ARCHITECT  i1000SR®  (Abbott)  equipment.  The
anufacturer’s instructions  were  followed  in  all  procedures.
uantiﬁcation of  the  immunosuppressant  was  reported  in
g/ml.
.3.  Quantiﬁcation  of  tacrolimus  in  whole  blood
or  quantiﬁcation  of  tacrolimus,  pre-treatment  was  carried
ut by  placing  a  sample  of  200  l whole  blood  and  200  l of
 precipitating  reagent  (ARCHITECT  Tacrolimus  Whole  Blood
recipitation Reagent®,  Abbott)  in  a  centrifuge  tube  and
hen using  vortex  agitation  for  7  min.  It  was  then  centrifuged
or 7  min  at  13,000  rpm,  and  the  supernatant  was  separated
n a  pretreatment  tube  for  immunosuppressive  techniques
1P06-01®, Abbott  Laboratories).  The  mixture  was  spun  for
0 sec  and  quantiﬁed  in  the  ARCHITECT  i1000SR®  (Abbott)
quipment.
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.4.  Quantiﬁcation  of  CMV
uantiﬁcation  of  CMV  was  done  in  whole  blood  and  plasma
ith real-time  PCR.  For  this  procedure,  3  ml  of  peripheral
lood was  obtained  anticoagulated  with  EDTA.  An  aliquot  of
00 l was  separated.  The  remaining  sample  was  centrifuged
t 3000  rpm  for  10  min  and  an  aliquot  of  400  l  of  plasma  was
aken. For  extraction  of  the  DNA  the  MagNA  Pure  Compact®
Roche Molecular  Diagnostics)  equipment  was  used  with  a
et of  reagents  using  MagNA  Pure  Compact  Nucleic  Acid
solation Kit  I (Roche  Molecular  Diagnostics).  Programs  for
NA extraction  from  400  l of  peripheral  blood  were  used
ith an  emulsion  volume  of  200  l,  and  the  program  of
otal nucleic  acids  from  400  l  of  plasma  with  an  emul-
ion volume  of  100  l. For  real-time  PCR  a  166-bp  fragment
f the  CMV  viral  genome  was  ampliﬁed  a  design  from  the
IB MOLBIOL  Company  and  LightCycler®  equipment  (Roche
olecular Diagnostics).  As  internal  positive  control  (human
lbumin), a  set  of  primers  that  ampliﬁes  a  278-bp  fragment
as used.  Primer  sequences  against  CMV  and  the  albumin
ene are  not  speciﬁed  by  the  supplier.  The  reaction  mixture
as brought  to  a  ﬁnal  volume  of  20  l  using  5  l  of  the  DNA
xtracted from  each  of  the  samples.  The  reaction  mixtures
ere subjected  to  a  program  of  denaturation  of  the  sample
nd activation  of  the  enzyme  at  a  temperature  of  95 ◦C  for
0 min,  followed  by  50  ampliﬁcation  cycles  of  5  sec  at  95 ◦C,
0 sec  at  60 ◦C,  15  sec  at  72 ◦C.  Later,  a denaturation  curve
as performed  to  identify  the  product  of  the  PCR  derived
rom the  DNA  of  the  CMV,  with  a  program  of  1  cycle  for
0 sec  at  95 ◦C,  20  sec  at  40 ◦C  and  1  sec  at  85 ◦C,  with  an
ncrease in  temperature  of  0.2 ◦C  sec  and  continuous  ﬂuo-
escence acquisition  mode.  The  manufacturer’s  instructions
ere followed  in  all  cases  (Roche  Molecular  Diagnostics).
.5.  Statistical  analysis
o  evaluate  the  correlation  between  study  variables,  Pear-
on correlation  coefﬁcient  (r)  and  its  respective  statistical
alue (two-tailed  p value)  were  obtained;  p  <  0.05  was  con-
idered to  be  statistically  signiﬁcant.  The  statistical  package
raphPad Prism  v.5.0  for  Windows  (GraphPad  Software,  La
olla  CA,  www.graphpad.com) was  used.
. Results
he  study  included  nine  patients  with  the  immunosupp-
essant sirolimus  and  46  patients  with  tacrolimus.  The
mmunosuppressant dose  varied  from  1  to  3  mg  every  24  h
or sirolimus  and  from  0.25  to  6  mg  every  12  h  for  tacrolimus.
igure 1  represents  the  correlation  between  the  dose  admin-
stered and  the  levels  of  immunosuppressant  in  the  blood.
here were  13  measurements  done  for  sirolimus  and  528
or tacrolimus.  A  positive  correlation  was  found  between
ariables in  both  cases,  although  the  Pearson  correlation
oefﬁcient (r)  was  very  close  to  zero  (r  =  0.0747  for  sirolimus
nd r  =  0.3037  for  tacrolimus).  In  the  latter  case,  the  corre-
ation was  statistically  signiﬁcant  (p  =  0.0001).  However,  this
eans that  only  with  a  30%  certainty  could  one  predict  the
lood concentration  of  tacrolimus  with  respect  to  the  dose
dministered. In  relation  to  sirolimus,  there  was  no  corre-
ation observed  between  the  dose  and  the  concentration
CMV  and  immunosuppressive  drugs  in  transplant  patients  7
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Figure  1  Comparison  of  dose  vs.  concentration  in  blood  of  the  im
patients).  (B)  Tacrolimus  (528  measurements  from  46  patients).  Pea
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Figure  2  Comparison  of  the  CMV  viral  load  in  plasma  and
whole blood.  Pearson  correlation  coefﬁcient  (r)  is  shown  for
the comparison.  Discordant  measurements  are  shown  in  red  in
which the  viral  load  was  elevated  in  plasma,  but  not  in  whole
blood or  vice-versa.  A  10-base  logarithmic  scale  was  used  for
the graph  in  order  to  better  separate  the  data,  although  the
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the CMV  viral  load  were  carried  out.  Data  obtained  showPearson correlation  was  calculated  linearly.
in  blood  (p  =  0.79).  Viral  load  of  CMV  in  plasma  vs.  whole
blood was  compared  with  the  objective  of  identifying  the
variation shown  between  both  biological  sources  (Fig.  2).
A positive  high  and  statistically  signiﬁcant  correlation  was
found (r  =  0.9406,  p  =  0.0001),  which  indicates  that  both
plasma as  well  as  whole  blood  reliably  reﬂect  the  behavior
of CMV  in  the  patient  with  immunosuppressive  treatment.
In nine  measurements,  the  correlation  between  samples
was very  poor,  with  values  >  5000  copies/ml  in  plasma  vs.
100 copies/ml  in  whole  blood  or  vice-versa,  values  >  5,000
copies/ml in  whole  blood  and  values  ≤100  copies/ml  in
plasma. These  cases  are  shown  in  red  points  in  Figure  2.
With  the  aim  of  determining  if  plasma  or  whole  blood  bet-
ter reﬂects  viral  replication,  the  correlation  between  viral
load in  plasma  or  whole  blood  and  the  levels  of  immuno-
suppressant were  analyzed.  According  to  Figure  3  and  as
expected, there  were  very  similar  degrees  of  correlation
found between  the  levels  of  immunosuppressant  and  viral
load, both  in  plasma  as  in  whole  blood.  However,  this  rela-
tionship had  values  very  close  to  zero.  The  latter  indicates
that the  evaluation  of  the  immunosuppressant  in  blood  does
not allow  predicting  if  the  patient  has  an  elevated  CMV  load
and therefore  is  at  risk  to  develop  an  associated  morbid-
ity. For  this  reason,  it  is  necessary  to  monitor  the  viral  load
i
N
dmunosuppressant.  (A)  Sirolimus  (13  measurements  from  nine
rson  correlation  coefﬁcient  (r)  is  shown  for  each  comparison.
ogether  with  immunosuppressant  levels  in  the  blood.  All  r
alues and  the  respective  p  value  are  shown  in  the  graphs.
.  Discussion
s  a strategy  to  prevent  graft  rejection  and  graft  vs.  host
isease, patients  who  receive  SOT  should  be  pharmaco-
ogically immunosuppressed.  However,  as  a result  of  this
mmunosuppression, post-transplant  patients  are  at  risk  of
eveloping severe  infections.12,17--19 Of  particular  impor-
ance is  infection  by  the  herpesvirus  family.  More  than
0% of  the  adult  population  is  infected  by  one  or  various
erpesviruses, although  the  infection  is  latent  and  asymp-
omatic in  healthy  individuals.  The  same  does  not  occur
n individuals  undergoing  immunosuppressive  treatment.  In
hese patients,  the  equilibrium  of  the  infection  is  altered
nd patients  can  develop  severe,  life-threatening  diseases.
mong the  common  problems  due  to  herpesviruses  that
resent in  patients  with  immunosuppressive  management
re severe  CMV  infections  and  lymphoproliferative  disease
ue to  the  Epstein-Barr  virus  (EBV).20 On  the  other  hand,
educing the  dose  of  the  immunosuppressant  drug  increases
he risk  of  transplant  rejection  and  graft  vs.  host  disease,
hich is  also  associated  with  increased  mortality  of  the
ransplant patient.
Despite  the  increasingly  larger  number  of  immuno-
uppressant drugs  available  on  the  market,  the  risk  of
evere infection  by  herpesviruses  continues.  Tacrolimus  and
irolimus are  two  of  the  main  immunosuppressant  drugs  used
orldwide.21 Both  have  very  similar  structures  and  recog-
ize FKBP12,  a  chaperone  protein  member  of  the  family
f the  immunophilins.22 These  compounds  were  originally
solated from  Streptomyces  hygroscopicus  by  its  potent
mmunosuppressive activity.  Because  both  drugs  efﬁciently
nd speciﬁcally  abate  the  cytotoxic  immune  response,  they
re widely  used  to  prevent  risk  of  transplant  rejection.  How-
ver, decrease  of  the  cytotoxic  immune  response  results  in
oss of  infection  control  by  herpesviruses.
This  present  study  analyzed  55  transplant  patients
reated with  sirolimus  or  tacrolimus  from  which  541  deter-
inations of  the  circulating  levels  of  the  drugs  and  ofnteresting trends  and  assist  clinically  in  patient  follow-up.
o signiﬁcant  association  was  found  between  medication
ose and  blood  levels.  This  was  reproduced  for  both
8  H.  Reyes-Pérez  et  al.
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Figure  3  Concentration  of  sirolimus  (A-B)  and  tacrolimus  (C-D)  vs.  viral  load  in  plasma  (A,C)  or  whole  blood  (B,D).  Pearson
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gorrelation coefﬁcient  (r)  is  shown  for  each  comparison.  Numb
rder  to  better  separate  the  data,  although  Pearson  correlation
mmunosuppressant  agents  analyzed  indicating  that  contin-
ous drug  monitoring  is  necessary  to  have  a  better  idea
f its  pharmacological  effect  and  patient  protection.  Both
mmunosuppressant agents,  sirolimus  and  tacrolimus,  have
 low  therapeutic  index.  Therefore  they  are  considered
s monitoring  drugs  because  their  circulation  levels  must
e constantly  evaluated.23 This  is  due  to  the  variability  of
he pharmacodynamic  and  pharmacokinetic  characteristics
etween patients.  The  data  presented  agree  with  the  above
nformation.
The herpesviruses  have  a  two-phase  life  cycle:  latent  and
ytic. The  latent  phase  is  associated  with  a  cellular  depend-
ncy in  which  there  is  not  production  of  viral  particles.
n the  contrary,  the  lytic  phase  could  be  associated  with
iremia. For  this  reason,  it  is  important  to  ask  oneself:  which
s the  best  source  of  clinical  sample  for  CMV  analysis?  The
ata observed  support  that,  for  CMV,  there  is  a  very  close
orrelation between  viral  load  present  in  whole  blood  and
n plasma,  at  least  in  patients  who  are  pharmacologically
mmunosuppressed.  Therefore,  with  few  exceptions,  both
lasma as  well  as  whole  blood  allow  us  to  have  a  good  idea
f the  viral  expansion  processes  due  to  de  novo  infection
r reactivation  that  a  transplant  patient  is  experiencing.
f the  541  measurements  done,  in  only  nine  there  were
alues found  that  did  not  correlate  in  which  one  of  the
easurements (in  plasma  or  whole  blood)  showed  values
5000 copies  of  CMV/ml,  whereas  the  other  measurement
howed negative  or  barely  detectable  CMV  values.  To  date
here is  no  consensus  about  the  levels  of  CMV  that  require
herapeutic intervention,  but  the  internal  recommendation
E
P
df  copies  of  CMV  was  graphed  in  a  10-base  logarithmic  scale  in
 calculated  linearly.
n  different  transplant  centers  is  from  ≥5,000  copies  of
MV/ml.24
These  data  also  support  that  the  continuous  monitoring
f the  viral  load  in  transplant  patients  is  necessary  because
ystemic levels  of  the  immunosuppressant  do  not  permit
redicting the  behavior  of  CMV.  This  is  illustrated  not  only
y the  values  of  the  Pearson  correlation  obtained  but  also
y the  patients  with  acceptable  immunosuppressive  levels
r higher  than  recommended  for  age  (>10  ng/ml)  and  viral
oads >  5,000  copies/ml.
In  summary,  the  dose  of  the  immunosuppressant  drug
oes not  correlate  with  levels  in  peripheral  blood.  For  this
eason, these  levels  should  be  constantly  monitored  along
ith the  CMV  load.  Viral  load  measured  in  whole  blood  or
lasma was  found  to  have  a  high  correlation,  indicating  that
oth types  of  clinical  samples  are  equally  reliable  in  reﬂect-
ng the  processes  of  infection/reactivation  by  CMV  due  to
he immunosuppression  that  the  transplanted  patient  is
xperiencing. Follow-up  of  the  transplanted  patient  through
uantiﬁcation of  the  systemic  levels  of  the  immunosuppress-
nt drugs  and  of  the  viral  loads  of  CMV  allows  the  physician
o intervene  before  the  patient  presents  a  serious  clinical
omplication. This  routine  analysis  of  transplanted  patients
llows for  a  higher  survival  rate  of  the  patients  and  the
rafts.thical disclosure
rotection  of  human  and  animal  subjects.  The  authors
eclare that  the  procedures  followed  were  in  accordance
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